GRACEcast
Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.
Visit Show Website http://cancerGRACE.org/Recently Aired
-
HD
Dr. Greg Riely: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
Dr. Greg Riely, from Memorial Sloan-Kettering, gives her view on ...
Dr. Greg Riely, from Memorial Sloan-Kettering, gives her view on more widespread availability of new mutation tests.
-
HD
Is there a place for maintenance therapy in extensive stage NSCLC?
Drs. Mary Pinder, Nate Pennell, and Jack West discuss whether ...
Drs. Mary Pinder, Nate Pennell, and Jack West discuss whether the finding of improving progression-free survival with maintenance sorafenib for SCLC should change the standard of care for treatment of extensive stage disease.
-
HD
How should we integrate new immunotherapies into treatment strategies for lung cancer?
Drs. Jack West, Mary Pinder, and Nate Pennell review various ...
Drs. Jack West, Mary Pinder, and Nate Pennell review various ways in which emerging immunotherapies could be effectively incorporated into our treatment strategies for lung cancer, potentially adding to or replacing current options.
-
HD
How do we approach acquired resistance to targeted therapies in lung cancer?
Drs. Jack West, Mary Pinder, and Nate Pennell discuss options ...
Drs. Jack West, Mary Pinder, and Nate Pennell discuss options for managing acquired resistance to EGFR TKIs and ALK inhibitors in patients with advanced NSCLC and a driver mutation.
-
HD
What have we learned from the START trial of immunotherapy in locally advanced NSCLC?
Drs. Nate Pennell, Mary Pinder, and Jack West discuss the ...
Drs. Nate Pennell, Mary Pinder, and Jack West discuss the START trial of L-BLP-25 (tecemotide) immunotherapy in locally advanced NSCLC.
-
HD
Dr. Phil Bonomi: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy
Dr. Phil Bonomi, from Rush University, reviews his thought process ...
Dr. Phil Bonomi, from Rush University, reviews his thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.
-
HD
Dr. Rosalyn Juergens: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?
Dr. Rosalyn Juergens, McMaster University, reviews how she discusses the ...
Dr. Rosalyn Juergens, McMaster University, reviews how she discusses the potential advantages and disadvantages waiting on molecular marker results and sometimes seeking additional tissue in patients with advanced NSCLC.
-
HD
Can we target KRAS effectively in advanced NSCLC?
Drs. Mary Pinder, Nate Pennell, and Jack West discuss developments ...
Drs. Mary Pinder, Nate Pennell, and Jack West discuss developments with selumetinib and other MEK inhibitors as a potential target for the 20-25% of NSCLC patients with a KRAS mutation.
-
HD
Dr. Geoffrey Oxnard: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?
Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes which patients ...
Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.
-
HD
Could BRAF be a new target in NSCLC?
Drs. Nate Pennell, Mary Pinder, and Jack West discuss an ...
Drs. Nate Pennell, Mary Pinder, and Jack West discuss an encouraging study of dabrafenib, a BRAF inhibitor, for the limited number of NSCLC patients with a BRAF V600E mutation.
